Advances in small molecule therapy for treating metastatic thyroid cancer

References

• Sherman SI. Thyroid carcinoma. Lancet (London, England). 2003;361(9356):501–511. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12583960
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638–2648.
   PubMed Web of Science ®Google Scholar
• Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–1335. DOI:10.1002/cncr.20936
   PubMed Web of Science ®Google Scholar
• Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–464. DOI:10.1245/ASO.2006.05.042
   PubMed Web of Science ®Google Scholar
• Bisof V, Rakusic Z, Despot M. Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made? Eur Arch Otorhinolaryngol. 2015;272(7):1553–1567. DOI:10.1007/s00405-014-3108-1
   PubMed Web of Science ®Google Scholar
• Mohebati A, Dilorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol. 2014;21(5):1665–1670. DOI:10.1245/s10434-014-3545-5
   PubMed Web of Science ®Google Scholar
• Paunovic IR, Sipetic SB, Zoric GV, et al. Survival and prognostic factors of anaplastic thyroid carcinoma. Acta Chir Belg. 2015;115(1):62–67. DOI:10.1080/00015458.2015.11681068.
   Web of Science ®Google Scholar
• Sampson E, Brierley JD, Le LW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110(7):1451–1456. DOI:10.1002/cncr.22956
   PubMed Web of Science ®Google Scholar
• Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22(9):884–889. DOI:10.1089/thy.2011.0535
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428.
   PubMed Web of Science ®Google Scholar
• Jarząb B, Dedecjus M, Handkiewicz-Junak D, et al. Diagnostics and treatment of thyroid carcinoma. Endokrynol Pol. 2016;67(1):74–107. DOI:10.5603/EP.2016.0011
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133. DOI:10.1089/thy.2015.0020.
   PubMed Web of Science ®Google Scholar
• Wassermann J, Bernier M-O, Spano J-P, et al. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist. 2016;21(1):50–58. DOI:10.1634/theoncologist.2015-0107
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899. DOI:10.1210/jc.2005-2838
   PubMed Web of Science ®Google Scholar
• Massicotte M-H, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170(4):575–582. DOI:10.1530/EJE-13-0825
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–2142. DOI:10.1002/cncr.22244
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 [cited 2015 Jul 28];12(12):1671-80; quiz 1680. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25505208
   PubMed Web of Science ®Google Scholar
• Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. DOI:10.1089/thy.2014.0335.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Bastholt L, Dralle H, et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5–14. DOI:10.1159/000336977.
   PubMedGoogle Scholar
• Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–1139. DOI:10.1089/thy.2012.0302.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol (Lausanne). 2015;6:176. DOI:10.3389/fendo.2015.00176
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328. DOI:10.1016/S0140-6736(14)60421-9.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. DOI:10.1056/NEJMoa1406470.
   PubMed Web of Science ®Google Scholar
• Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141. DOI:10.1200/JCO.2011.35.5040.
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. DOI:10.1200/JCO.2012.48.4659.
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–4719. DOI:10.1200/JCO.2008.16.3279
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, M V K, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–1684. DOI:10.1200/JCO.2008.18.2717
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923–931. DOI:10.1530/EJE-09-0702
   PubMed Web of Science ®Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165(2):315–322. DOI:10.1530/EJE-11-0129
   PubMed Web of Science ®Google Scholar
• Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012;19(2):209–216. DOI:10.1530/ERC-11-0351
   PubMed Web of Science ®Google Scholar
• Dadu R, Waguespack SG, Sherman SI, et al. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014;19(5):477–482. DOI:10.1634/theoncologist.2013-0409
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Politti U, Spisni R, et al. Sorafenib in the treatment of thyroid cancer. Expert Rev Anticancer Ther. 2015;15(8):863–874. DOI:10.1586/14737140.2015.1064770
   PubMed Web of Science ®Google Scholar
• Krajewska J, Handkiewicz-Junak D, Jarzab B. Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin Pharmacother. 2015;16(4):573–583. DOI:10.1517/14656566.2015.1005601
   PubMed Web of Science ®Google Scholar
• Shen C-T, Qiu Z-L, Luo Q-Y. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer. 2014;21(2):253–261. DOI:10.1530/ERC-13-0438
   PubMed Web of Science ®Google Scholar
• Brose M, Jarzab B, Elisei R, et al. Updated overall survival analysis of patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer treated with sorafenib on phase 3 DECISION trial (ABSTRACT). J Clin Oncol. 2014;32(15 Suppl):6060.
   Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–2756. DOI:10.1002/cncr.29395
   PubMed Web of Science ®Google Scholar
• Robinson B, Schlumberger M, Wirth LJ, et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016;101(11):4103–4109. DOI:10.1210/jc.2015-3989
   PubMed Web of Science ®Google Scholar
• Brose M, Worden FP, Newbold KL, et al.  Effect of age on the efficacy and safety of lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer in the Phase III SELECT trial. J Clin Oncol. 2017. DOI:10.1200/JCO.2016.71.6472. [Epub ahead of print]
   Google Scholar
• Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–772. DOI:10.1200/JCO.2009.23.6604
   PubMed Web of Science ®Google Scholar
• Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2664–2671. DOI:10.1210/jc.2009-2461
   PubMed Web of Science ®Google Scholar
• Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013;19(15):4239–4248. DOI:10.1158/1078-0432.CCR-13-0071
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–2666. DOI:10.1200/JCO.2010.32.4145
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Elisei R, Muller S, et al. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients with documented RECIST progression at baseline. J Clin Oncol. 2015;33:6012.
   Web of Science ®Google Scholar
• Krajewska J, Olczyk T, Jarzab B. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert Rev Clin Pharmacol. 2016;9(1):69–79. DOI:10.1586/17512433.2016.1102052
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323–2330. DOI:10.1200/JCO.2009.25.0068
   PubMed Web of Science ®Google Scholar
• Cappagli V, Bottici V, Molinaro E, et al. Metastatic thyroid cancer unresponsive to conventional therapy treated with sorafenib “off-label”: an update of our 6 years of experience (ABSTRACT). Eur Thyroid J. 2014;3(suppl 1):103.
   Google Scholar
• Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23(5):600–604. DOI:10.1089/thy.2012.0103
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Jarzab B, Cabanillas ME, et al. A Phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44–53. DOI:10.1158/1078-0432.CCR-15-1127
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905. DOI:10.1016/S1470-2045(12)70335-2
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Brose MS, Holland J, et al. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014;24(10):1508–1514. DOI:10.1089/thy.2014.0125
   PubMed Web of Science ®Google Scholar
• de Groot JWB, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466–3469. DOI:10.1210/jc.2007-0649
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Fabel M, Delorme S, et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157(2):215–220. DOI:10.1530/EJE-06-0695
   PubMed Web of Science ®Google Scholar
• Whang YE, Tran C, Henderson C, et al. c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci U S A. 2000 [cited 2017 Mar 18];97(10):5486–5491. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/10805805
   PubMed Web of Science ®Google Scholar
• Podtcheko A, Ohtsuru A, Tsuda S, et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 2003;88(4):1889–1896. DOI:10.1210/jc.2002-021230
   PubMed Web of Science ®Google Scholar
• Kurebayashi J, Okubo S, Yamamoto Y, et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol. 2006;58(4):460–470. DOI:10.1007/s00280-006-0185-x
   PubMed Web of Science ®Google Scholar
• Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975–980. DOI:10.1089/thy.2010.0057
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42. DOI:10.1056/NEJMoa075853
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27(23):3794–3801. DOI:10.1200/JCO.2008.18.7815
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–972. DOI:10.1016/S1470-2045(10)70203-5
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99(5):1687–1693. DOI:10.1210/jc.2013-3713
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):3179–3184. DOI:10.1210/jc.2012-1520
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474–5483. DOI:10.1200/JCO.2005.04.192
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713. DOI:10.1200/JCO.2007.15.9566
   PubMed Web of Science ®Google Scholar
• Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014;120(17):2694–2703. DOI:10.1002/cncr.28766
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–5268. DOI:10.1158/1078-0432.CCR-10-0994
   PubMed Web of Science ®Google Scholar
• Ravaud A, De La Fouchardière C, Asselineau J, et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist. 2010;15(2):212-3; author reply 214. DOI:10.1634/theoncologist.2009-0303
   PubMed Web of Science ®Google Scholar
• Ravaud A, De La Fouchardière C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 2017;76:110–117. DOI:10.1016/j.ejca.2017.01.029
   PubMed Web of Science ®Google Scholar
• D’Agostino M, Voce P, Celano M, et al. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid. 2012;22(2):138–144. DOI:10.1089/thy.2011.0060
   PubMed Web of Science ®Google Scholar
• Díez JJ, Iglesias P, Alonso T, et al. Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice. Endocrine. 2015;48(2):582–588. DOI:10.1007/s12020-014-0356-1
   PubMed Web of Science ®Google Scholar
• Atallah V, Hocquelet A, Do Cao C, et al. Activity and safety of sunitinib in patients with advanced radioiodine refractory thyroid carcinoma: a retrospective analysis of 57 patients. Thyroid. 2016;26(8):1085–1092. DOI:10.1089/thy.2015.0648
   PubMed Web of Science ®Google Scholar
• Cleary JM, Sadow PM, Randolph GW, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol. 2010;28(23):e390–2. DOI:10.1200/JCO.2009.27.4225
   PubMed Web of Science ®Google Scholar
• Bikas A, Kundra P, Desale S, et al. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer. Eur J Endocrinol. 2016;174(3):373–380. DOI:10.1530/EJE-15-0930
   PubMed Web of Science ®Google Scholar
• Marotta V, Di Somma C, Rubino M, et al. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. Endocrine. 2015;49(3):854–858. DOI:10.1007/s12020-014-0448-y
   PubMed Web of Science ®Google Scholar
• Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–1282. DOI:10.1016/S1470-2045(16)30166-8
   PubMed Web of Science ®Google Scholar
• Krajewska J, Rusinek D, Jarzab B. Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat? Transl Cancer Res. 2016;5:S1340-S1344. DOI:10.21037/tcr.2016.12.20
   Web of Science ®Google Scholar
• Dadu R, Shah K, Busaidy NL, et al. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015;100(1):E77–81. DOI:10.1210/jc.2014-2246
   PubMed Web of Science ®Google Scholar
• Dao BD, Lingvay I, Sailors J, et al. First-line use of vemurafenib to enable thyroidectomy and radioactive iodine ablation for BRAF-positive metastatic papillary thyroid carcinoma: a case report. J Invest Med High Impact Case Rep. 2015;3(3). DOI:10.1177/2324709615603723
   PubMedGoogle Scholar
• Falchook GS, Millward M, Hong D, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015;25(1):71–77. DOI:10.1089/thy.2014.0123
   PubMed Web of Science ®Google Scholar
• Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–632. DOI:10.1056/NEJMoa1209288
   PubMed Web of Science ®Google Scholar
• Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24(12):3089–3094. DOI:10.1093/annonc/mdt379
   PubMed Web of Science ®Google Scholar
• Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial. J Clin Endocrinol Metab. 2016;jc20162525. DOI:10.1210/jc.2016-2525.
   Web of Science ®Google Scholar
• Faggiano A, Ramundo V, Dicitore A, et al. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med. 2012;16(7):1563–1572. DOI:10.1111/j.1582-4934.2011.01438.x
   PubMed Web of Science ®Google Scholar
• Schneider TC, de Wit D, Links TP, et al. Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a Phase II trial. Int J Endocrinol. 2015;2015:1–8. DOI:10.1155/2015/348124
   Web of Science ®Google Scholar
• Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426–1433. DOI:10.1056/NEJMoa1403352
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, Fallahi P, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014;99(4):E572–E581. DOI:10.1210/jc.2013-2321
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol. 2014;393(1–2):56–64. DOI:10.1016/j.mce.2014.06.002
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. Endocrinology. 2011;152(1):334–334. DOI:10.1210/endo.152.1.9995
   Google Scholar
• Nagayama Y, Shimamura M, Mitsutake N. Cancer stem cells in the thyroid. Front Endocrinol (Lausanne). 2016;7:20. DOI:10.3389/fendo.2016.00020
   PubMed Web of Science ®Google Scholar
• Vicari L, Colarossi C, Giuffrida D, et al. Cancer stem cells as a potential therapeutic target in thyroid carcinoma (Review). Oncol Lett. 2016;12(4):2254–2260. DOI:10.3892/ol.2016.4936
   PubMed Web of Science ®Google Scholar
• Hardin H, Zhang R, Helein H, et al. The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors. Lab Invest. 2017. DOI:10.1038/labinvest.2017.41.
   PubMedGoogle Scholar
• Krajewska J, Paliczka-Cieslik E, Jarzab B. Managing tyrosine kinase inhibitors side effects in thyroid cancer. Expert Rev Endocrinol Metab. 2017;12:117–127. DOI:10.1080/17446651.2017.1300526
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Patel A, Danysh BP, et al. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Horm Cancer. 2015;6(1):21–36. DOI:10.1007/s12672-014-0207-9
   PubMed Web of Science ®Google Scholar
• Shen C-T, Qiu Z-L, Luo Q-Y. Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014 [cited 2017 Mar 23];15(5):2369–2374. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/24716986
   PubMedGoogle Scholar
• de Wit D, Schneider TC, Moes DJAR, et al. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol. 2016;78(1):63–71. DOI:10.1007/s00280-016-3050-6
   PubMed Web of Science ®Google Scholar
• French JD, Bible K, Spitzweg C, et al. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017;5(6):469–481. DOI:10.1016/S2213-8587(16)30277-7
   PubMed Web of Science ®Google Scholar
• Bible KC, Cote GJ, Demeure MJ, et al. Correlative studies in clinical trials: a position statement from the International Thyroid Oncology Group. J Clin Endocrinol Metab. 2015;100(12):4387–4395. DOI:10.1210/jc.2015-2818
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat—and with which drug—those are the questions. J Clin Endocrinol Metab. 2014;99(12):4390–4396. DOI:10.1210/jc.2014-2811
   PubMed Web of Science ®Google Scholar
• Brose MS, Smit JW, Lin C-C, et al. Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocr Relat Cancer. 2017;ERC-17-0016. DOI:10.1530/ERC-17-0016.
   PubMed Web of Science ®Google Scholar